MX2019002121A - Tratamiento conjunto para tratar el cancer de pancreas. - Google Patents
Tratamiento conjunto para tratar el cancer de pancreas.Info
- Publication number
- MX2019002121A MX2019002121A MX2019002121A MX2019002121A MX2019002121A MX 2019002121 A MX2019002121 A MX 2019002121A MX 2019002121 A MX2019002121 A MX 2019002121A MX 2019002121 A MX2019002121 A MX 2019002121A MX 2019002121 A MX2019002121 A MX 2019002121A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- pancreatic cancer
- treatment
- combination therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
El objeto descrito en la presente se dirige a composiciones que comprenden un inhibidor de MEK, o una de sus sales aceptables desde el punto de vista farmacéutico, y un inhibidor de múltiples quinasas que se dirige a PDGFRa, S6 y STAT3 o una de sus sales aceptables desde el punto de vista farmacéutico, y su uso para tratar el cáncer de páncreas. En otro aspecto, en la presente se describen métodos para tratar el cáncer de páncreas mediante la administración de un inhibidor de MEK, o una de sus sales aceptables desde el punto de vista farmacéutico, y un inhibidor de múltiples quinasas, o una de sus sales aceptables desde el punto de vista farmacéutico. En otro aspecto, la combinación de cobimetinib, o una de sus sales aceptables desde el punto de vista farmacéutico, y ponatinib o una de sus sales aceptables desde el punto de vista farmacéutico, se administra en una composición o la combinación se administra de manera separada para tratar el cáncer de páncreas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378322P | 2016-08-23 | 2016-08-23 | |
| PCT/US2017/047985 WO2018039211A1 (en) | 2016-08-23 | 2017-08-22 | Combination therapy for the treatment of pancreatic cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019002121A true MX2019002121A (es) | 2019-08-12 |
Family
ID=59762090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002121A MX2019002121A (es) | 2016-08-23 | 2017-08-22 | Tratamiento conjunto para tratar el cancer de pancreas. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10933058B2 (es) |
| EP (1) | EP3503922B1 (es) |
| JP (1) | JP2019526559A (es) |
| KR (1) | KR20190039951A (es) |
| CN (1) | CN109641058A (es) |
| AU (1) | AU2017316618A1 (es) |
| BR (1) | BR112019002945A2 (es) |
| CA (1) | CA3034259A1 (es) |
| IL (1) | IL264589A (es) |
| MX (1) | MX2019002121A (es) |
| WO (1) | WO2018039211A1 (es) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021081554A1 (en) * | 2019-10-22 | 2021-04-29 | Chemistryrx | Methods for treating congenital epidermal hyperplasia |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109641058A (zh) * | 2016-08-23 | 2019-04-16 | 吉宁特有限公司 | 治疗胰腺癌的组合疗法 |
| US20210220471A1 (en) * | 2018-07-13 | 2021-07-22 | Memorial Sloan Kettering Cancer Center | Methods of using pharmacologic inhibitors of type 2 cytokine signaling to treat or prevent pancreatic cancer |
| CN115243719A (zh) * | 2020-03-06 | 2022-10-25 | 北京先通生物医药技术有限公司 | CTB006与Ponatinib联合应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US9532987B2 (en) * | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| US10428387B2 (en) * | 2014-05-16 | 2019-10-01 | University Of Massachusetts | Treating chronic myelogenous leukemia (CML) |
| WO2016123054A2 (en) * | 2015-01-26 | 2016-08-04 | The University Of North Carolina At Chapel Hill | Kinase drug combinations and methods of use thereof |
| US10792284B2 (en) * | 2015-02-12 | 2020-10-06 | Memorial Sloan Kettering Cancer Center | Synergistic cancer treatment |
| CN109641058A (zh) * | 2016-08-23 | 2019-04-16 | 吉宁特有限公司 | 治疗胰腺癌的组合疗法 |
-
2017
- 2017-08-22 CN CN201780051187.XA patent/CN109641058A/zh active Pending
- 2017-08-22 EP EP17761408.8A patent/EP3503922B1/en active Active
- 2017-08-22 CA CA3034259A patent/CA3034259A1/en not_active Abandoned
- 2017-08-22 MX MX2019002121A patent/MX2019002121A/es unknown
- 2017-08-22 JP JP2019510651A patent/JP2019526559A/ja active Pending
- 2017-08-22 WO PCT/US2017/047985 patent/WO2018039211A1/en unknown
- 2017-08-22 AU AU2017316618A patent/AU2017316618A1/en not_active Abandoned
- 2017-08-22 KR KR1020197004431A patent/KR20190039951A/ko not_active Application Discontinuation
- 2017-08-22 BR BR112019002945-1A patent/BR112019002945A2/pt not_active IP Right Cessation
-
2019
- 2019-01-31 IL IL264589A patent/IL264589A/en unknown
- 2019-02-22 US US16/283,203 patent/US10933058B2/en active Active
-
2021
- 2021-02-19 US US17/180,522 patent/US20210283120A1/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021081554A1 (en) * | 2019-10-22 | 2021-04-29 | Chemistryrx | Methods for treating congenital epidermal hyperplasia |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109641058A (zh) | 2019-04-16 |
| BR112019002945A2 (pt) | 2019-05-21 |
| KR20190039951A (ko) | 2019-04-16 |
| IL264589A (en) | 2019-02-28 |
| EP3503922A1 (en) | 2019-07-03 |
| US10933058B2 (en) | 2021-03-02 |
| WO2018039211A1 (en) | 2018-03-01 |
| US20190175576A1 (en) | 2019-06-13 |
| CA3034259A1 (en) | 2018-03-01 |
| US20210283120A1 (en) | 2021-09-16 |
| EP3503922B1 (en) | 2022-10-26 |
| AU2017316618A1 (en) | 2019-02-07 |
| JP2019526559A (ja) | 2019-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021004821A (es) | Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. | |
| NZ738929A (en) | Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
| NZ739503A (en) | A novel approach for treatment of cancer using immunomodulation | |
| MX2018001659A (es) | Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer. | |
| MX2022005994A (es) | Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras. | |
| WO2016025635A3 (en) | Combination therapy for treating cancer | |
| MX2019012884A (es) | Terapia de combinacion. | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| SG10201902664RA (en) | Combination therapy for treating cancer | |
| MX2019002121A (es) | Tratamiento conjunto para tratar el cancer de pancreas. | |
| WO2016043874A3 (en) | Combination therapy for treating cancer | |
| WO2016133903A3 (en) | Combination therapy for cancer treatment | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| TW201613578A (en) | Pharmaceutical combinations | |
| MX2017015012A (es) | Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné. | |
| MX2019013862A (es) | Terapia de combinacion. | |
| EA035519B9 (ru) | 1,3,4-тиадиазольные соединения и их применение в лечении рака | |
| MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
| PH12020500666A1 (en) | Pladienolide compounds and their use | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| MX2023001425A (es) | Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer. | |
| BRPI0508982A (pt) | uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluindo um sal de maleato de azd2171, composição farmacêutica, kit, método para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, e, uso de sal de maleato de azd2171 e 5 - fu e cpt - 11 |